Developing a holistic contingency plan: Challenges and dilemmas for cancer patients during the COVID-19

被引:7
作者
Constantinou, Constantina [1 ]
Kolokotroni, Ourania [1 ]
Mosquera, Maria-Cecilia [1 ]
Heraclides, Alexandros [1 ]
Demetriou, Christiana [1 ]
Karayiannis, Peter [1 ]
Quattrocchi, Annalisa [1 ]
Charalambous, Andreas [1 ]
机构
[1] Univ Nicosia, Sch Med, Nicosia, Cyprus
来源
CANCER MEDICINE | 2020年 / 9卷 / 17期
关键词
cancer; contingency plan; COVID-19; management; prevention; CORONAVIRUS DISEASE 2019; OUTBREAK; RECOMMENDATIONS; SARS;
D O I
10.1002/cam4.3271
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
During the first quarter of 2020 the world is experiencing a pandemic of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), a novel beta coronavirus that is responsible for the 2019 novel coronavirus disease (COVID-19). The COVID-19 pandemic revealed that healthcare systems around the world were not prepared to deal with either the direct effects of the pandemic or with the indirect effects that are imposed on the health of patients with chronic disorders such as cancer patients. Some challenges and dilemmas currently faced during the pandemic include the management of cancer patients during the treatment and follow-up phases, the assessment of the safety of treatments currently used for the management of SARS-CoV-2 for use in cancer patients, the development of psychoeducation and emotional support for cancer patients and the safe conduct of clinical trials involving participation of cancer patients. Evidence from the literature supports the need for the urgent development of a holistic contingency plan which will include clear guidelines for the protection and comprehensive care of cancer patients. The implementation of such a plan is expected to have many beneficial effects by mainly minimizing the increased morbidity and mortality of cancer patients that could result as an adverse consequence of the COVID-19 or future pandemics.
引用
收藏
页码:6082 / 6092
页数:11
相关论文
共 91 条
  • [1] Adashek Jacob J, 2020, J Immunother Precis Oncol, V3, P49, DOI 10.4103/2666-2345.280883
  • [2] Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity
    Aguiar, Anna C. C.
    Murce, Erika
    Cortopassi, Wilian A.
    Pimentel, Andre S.
    Almeida, Maria M. F. S.
    Barros, Daniele C. S.
    Guedes, Jessica S.
    Meneghetti, Mario R.
    Krettli, Antoniana U.
    [J]. INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2018, 8 (03): : 459 - 464
  • [3] AKLADIOS C, 2020, J GYNECOL OBSTET HUM, V49
  • [4] Alipour S, 2020, ARCH BREAST CANC, V7, P1, DOI [10.19187/abc.2020711-3, DOI 10.19187/ABC.2020711-3]
  • [5] American College of Surgeons (ACS), 2020, COVID 19 UPD GUID TR
  • [6] American Society of Clinical Oncology (ASCO), ASCO COR RES
  • [7] American Society of Hematology, 2020, COVID 19 RES
  • [8] [Anonymous], 2020, Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)
  • [9] [Anonymous], 2020, HPSO PHYS THERAPY SP
  • [10] [Anonymous], 2020, GUIDANCE NIH FUNDED